• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Drugs » Antibody-drug conjugate

Antibody-drug conjugate
Antibody-drug conjugate RSS Feed RSS

Immuno-oncology

TROP2-targeting antibody-drug conjugate shows promising results in pancreatic cancer

April 28, 2025
Researchers from Heidelberg Pharma AG have presented a new antibody-drug conjugate (ADC) that shows promise for treating pancreatic ductal adenocarcinoma (PDAC). The ADC, called hRS7 ATAC, targets trophoblast cell surface antigen 2 (TROP2), which is overexpressed in most pancreatic tumors and is associated with aggressive disease and poor prognosis.
Read More
Dan Chen, founder and CEO, Synthetic Design Lab
Cancer

Synthetic Design emerges with $20M and next-gen ADC platform

April 25, 2025
By Jennifer Boggs
Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC) space, began with its founders identifying a single clear goal: how to deliver more payload to a target cancer cell.
Read More
Immuno-oncology

Kelun-Biotech′s ADC SKB-518 cleared to enter clinic in US

April 25, 2025
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has been granted IND clearance by the FDA for its antibody-drug conjugate (ADC) drug SKB-518.
Read More
Immuno-oncology

Tagworks advances TGW-101 into phase I following IND clearance

April 25, 2025
Tagworks Pharmaceuticals BV has received IND clearance from the FDA for a phase I trial evaluating its antibody-drug conjugate (ADC) TGW-101 in patients with advanced solid tumors. The company has initiated the first-in-human trial.
Read More
China in red on globe
Chinabio 2025

US capital crunch pushes China biotechs to roundabout financings

April 24, 2025
By Marian (YoonJee) Chu
Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings.
Read More
3D rendering of drug linked to antibody
Neurology/psychiatric

Antibody-drug conjugate shows preclinical promise to target fibrosis in DMD

April 24, 2025
Duchenne muscular dystrophy (DMD) is a devastating genetic disorder affecting approximately 1 in 3,500-5,000 newborn males worldwide. It is characterized by progressive degeneration of skeletal, cardiac and smooth muscle, leading to early mortality. A team of researchers from the Technion Israel Institute of Technology has developed a novel approach to combat fibrosis in DMD.
Read More
Handshake with digital globe overlay

Chinabio 2025: Europe-China pharma deals rise as US markets shut

April 23, 2025
By Marian (YoonJee) Chu
Europe was a bigger counterpart to China in pharmaceutical dealmaking than the U.S. last year, speakers at Chinabio Partnering Forum said April 23, and the trend is likely to continue in 2025 with the shuttering of U.S. capital and volatility ailing global markets.
Read More

Duality Biotherapeutics raises $211M with Hong Kong IPO

April 22, 2025
By Marian (YoonJee) Chu
Antibody-drug conjugate developer Duality Biotherapeutics Inc. debuted on the Hong Kong Stock Exchange (HKEX) with a HK$1.64 billion (US$211.4 million) IPO April 15, making it one of the biggest offerings made under the HKEX’s Chapter 18A listing regime since 2020.
Read More
3D illustration demonstrating antibody-drug conjugate.
Immuno-oncology

1st Biotherapeutics and Ligachem Biosciences partner on ADC payloads and immuno-oncology candidates

April 22, 2025
1st Biotherapeutics Inc. and Ligachem Biosciences Inc. have entered into a strategic partnership and licensing option agreement.
Read More

Duality Biotherapeutics raises $211M with Hong Kong IPO

April 16, 2025
By Marian (YoonJee) Chu
Antibody-drug conjugate developer Duality Biotherapeutics Inc. debuted on the Hong Kong Stock Exchange (HKEX) with a HK$1.64 billion (US$211.4 million) IPO April 15, making it one of the biggest offerings made under the HKEX’s Chapter 18A listing regime since 2020.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 50 51 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • AI-generated illustration of CAR T cells

    Researchers arm CAR T cells to fight solid tumors

    BioWorld
    Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
  • Digital lungs illustration

    Bioversys, Shionogi in CHF529M lung infection collaboration

    BioWorld Science
    Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...
  • Medtronic Vitalflow ECMO

    Medtronic receives CE mark for its Vitalflow ECMO system

    BioWorld MedTech
    Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe